Company news

Shuttle Pharmaceuticals Holdings, Inc. news in 2024

Shuttle Pharmaceuticals Holdings, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program

December 18, 2024

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

November 25, 2024

Shuttle Pharma Pays Off Senior Secured Convertible Note

October 28, 2024

Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

October 28, 2024

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

October 28, 2024

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

October 27, 2024

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

September 15, 2024

Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease

September 4, 2024

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

September 3, 2024

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

August 27, 2024

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

August 25, 2024

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

August 13, 2024

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

June 17, 2024

Shuttle Pharma Provides First Quarter 2024 Corporate Update

May 13, 2024

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

March 20, 2024

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

February 12, 2024

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

January 7, 2024

Decks in 2024